CERS vs HAE
CERS: Cerus develops pathogen-inactivation technologies for blood transfusions and cellular therapy products, with the INTERCEPT Blood System as its lead commercial offering. HAE: Haemonetics provides automated plasma collection systems, blood processing devices, and hospital blood management technologies serving plasma centers, blood banks, and hospitals globally.
Side-by-side fundamentals
| Metric | CERS | HAE | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $3.02 | $78.03 | |
| Market cap as of 2026-07-23 | $625M | $3.5B | |
| P/E as of 2026-07-23 | n/a | 36.13 | |
| Net margin as of 2026-07-23 | -3.9% | +7.3% | HAE higher |
| Gross margin as of 2026-07-23 | +58.4% | +59.0% | HAE higher |
| Operating margin as of 2026-07-23 | -1.3% | +11.8% | HAE higher |
| ROE as of 2026-07-23 | -15.4% | +11.3% | HAE higher |
| ROA as of 2026-07-23 | -4.4% | +4.0% | HAE higher |
| Debt / equity as of 2026-07-23 | 1.26 | 1.54 | CERS lower |
| Revenue growth (YoY) as of 2026-07-23 | +18.4% | -2.0% | CERS higher |
| Revenue CAGR (3y) SEC XBRL | +7.5% | +4.5% | CERS higher |
| Beta as of 2026-07-23 | 1.75 | 0.53 | |
| 1-year return as of 2026-07-22 close | +111.2% | +5.8% | CERS higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.